India Approves Advaxis Trial In Cervix Cancer
Main Category: Cervical Cancer / HPV Vaccine
Article Date: 24 Sep 2010 - 1:00 PDT
As part of approving the human testing of ADXS11-001- the lead agent for the treatment of cervix cancer of Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company - the Drugs Controller General of India (DCGI) required that the agent be tested to assure its safety prior to use. Testing will be completed in ten days and patient dosing will begin.
Currently nine (9) centers have been enrolled and have begun to screen patients with advanced, metastatic cervix cancer for enrollment in this trial. These centers include Tata Memorial, Apollo Hospitals and other centers of medical research excellence in India. Full enrollment is anticipated in approximately three (3) months after the DCGI releases the drug for human use.
"This design advances the clinical development of ADXS 11-001 greatly in a number of ways," said Dr. John Rothman EVP of Science and Operations. "If we can duplicate the results of our phase I or improve upon them with three (3) doses of our agent compared to two(2) doses in Phase I, or find improved outcomes with chemotherapy, we would be able to show ADXS11-001 to be a safe and effective therapeutic agent where no alternatives exist."
Source:http://www.medicalnewstoday.com/articles/202234.php
OTHER LINKS
aCancer Herbal Treatment - Improves quality of life and health Increase Life expectancy Naturally - www.cowurine.net
Clinical Trials Articles - Free access to key research for Cochrane Colloquium Delegates - www.clinicaltrialarticles.com
Anticancer TCM Drug - KLT - Treat lung, liver, breast & other cancers with over 550,000 cases. - www.kanglaite.com
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment